Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Raised by Federated Hermes Inc.

Federated Hermes Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 11.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,446,500 shares of the biopharmaceutical company’s stock after purchasing an additional 250,000 shares during the quarter. Federated Hermes Inc. owned approximately 2.98% of Ultragenyx Pharmaceutical worth $116,992,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of RARE. Raymond James & Associates increased its stake in shares of Ultragenyx Pharmaceutical by 46.0% during the 1st quarter. Raymond James & Associates now owns 13,882 shares of the biopharmaceutical company’s stock worth $1,008,000 after purchasing an additional 4,373 shares during the last quarter. US Bancorp DE increased its stake in shares of Ultragenyx Pharmaceutical by 14.6% during the 1st quarter. US Bancorp DE now owns 8,611 shares of the biopharmaceutical company’s stock worth $625,000 after purchasing an additional 1,097 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Ultragenyx Pharmaceutical by 22.7% during the 1st quarter. Bank of Montreal Can now owns 40,319 shares of the biopharmaceutical company’s stock worth $2,927,000 after purchasing an additional 7,469 shares during the last quarter. MetLife Investment Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth $252,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Ultragenyx Pharmaceutical by 44.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 463,996 shares of the biopharmaceutical company’s stock worth $33,693,000 after purchasing an additional 141,945 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, insider John Richard Pinion sold 4,173 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $224,340.48. Following the completion of the transaction, the insider now directly owns 89,268 shares of the company’s stock, valued at approximately $4,799,047.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider John Richard Pinion sold 4,173 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $224,340.48. Following the completion of the transaction, the insider now directly owns 89,268 shares of the company’s stock, valued at approximately $4,799,047.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Thomas Richard Kassberg sold 11,509 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $49.93, for a total transaction of $574,644.37. Following the transaction, the executive vice president now directly owns 252,823 shares of the company’s stock, valued at $12,623,452.39. The disclosure for this sale can be found here. In the last three months, insiders sold 31,974 shares of company stock valued at $1,639,721. Company insiders own 6.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on RARE shares. Canaccord Genuity Group raised their target price on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, April 5th. Robert W. Baird raised their target price on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. Wedbush reiterated a “neutral” rating and issued a $48.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Finally, JPMorgan Chase & Co. raised their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.55.

Ultragenyx Pharmaceutical Stock Up 0.2 %

NASDAQ RARE traded up $0.11 during midday trading on Thursday, hitting $44.22. The company had a trading volume of 197,544 shares, compared to its average volume of 758,023. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of -5.30 and a beta of 0.65. The firm has a fifty day simple moving average of $48.14 and a two-hundred day simple moving average of $43.44. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $31.52 and a fifty-two week high of $54.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.65) by $0.13. The company had revenue of $127.39 million for the quarter, compared to analyst estimates of $119.38 million. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The business’s quarterly revenue was up 23.3% on a year-over-year basis. During the same period last year, the business posted ($2.16) EPS. As a group, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.36 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.